Your browser doesn't support javascript.
loading
Microsecretory Adenocarcinoma of Salivary Glands: An Expanded Series of 24 Cases.
Bishop, Justin A; Sajed, Dipti P; Weinreb, Ilan; Dickson, Brendan C; Bilodeau, Elizabeth A; Agaimy, Abbas; Franchi, Alessandro; Khurram, Syed Ali; Da Forno, Philip; Robledo, Juliana; Kalmar, John R; Aguirre, Sarah; Krane, Jeffrey F; Tapia, Jose Luis; Kiss, Katalin; Cordell, Kitrina; Rosebush, Molly; Barrett, A William; Oda, Dolphine; Assaad, Adel; Nagao, Toshitaka; Kawakami, Fumi; Nakaguro, Masato; Zahir, Ismail; Wakeman, Kristina; Ihrler, Stephan; Chenevert, Jacinthe; Lin, Yi-Ling; Westra, William H; Gagan, Jeffrey; Rooper, Lisa M.
Afiliação
  • Bishop JA; Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA. justin.bishop@utsouthwestern.edu.
  • Sajed DP; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
  • Weinreb I; Department of Pathology, University Health Network, Toronto, ON, Canada.
  • Dickson BC; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
  • Bilodeau EA; Department of Pathology & Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada.
  • Agaimy A; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
  • Franchi A; Department of Diagnostic Sciences, School of Dental Medicine, University of Pittsburgh, Pittsburgh, USA.
  • Khurram SA; Institute of Pathology, University Hospital of Erlangen, Erlangen, Germany.
  • Da Forno P; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Robledo J; Unit of Oral and Maxillofacial Pathology, School of Clinical Dentistry, 19 Claremont Crescent, Sheffield, S10 2TA, UK.
  • Kalmar JR; Department of Cellular Pathology, University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Aguirre S; Department of Pathology and Laboratory Medicine, Long School of Medicine, UT Health, San Antonio, TX, USA.
  • Krane JF; Division of Oral and Maxillofacial Pathology, The Ohio State University College of Dentistry, Columbus, OH, USA.
  • Tapia JL; Division of Oral and Maxillofacial Pathology, The University of Tennessee Health Science Center College of Dentistry, Memphis, TN, USA.
  • Kiss K; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.
  • Cordell K; Department of Oral Diagnostic Sciences, School of Dental Medicine, State University of New York at Buffalo, Buffalo, NY, USA.
  • Rosebush M; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Barrett AW; Department of Diagnostic Sciences, Louisiana State University Health Sciences Center School of Dentistry, New Orleans, LA, USA.
  • Oda D; Department of Diagnostic Sciences, Louisiana State University Health Sciences Center School of Dentistry, New Orleans, LA, USA.
  • Assaad A; Department of Histopathology, Queen Victoria Hospital, Holtye Road, East Grinstead, West Sussex, RH19 3DZ, UK.
  • Nagao T; Department Oral & Maxillofacial Surgery, School of Dentistry, University of Washington, Seattle, WA, USA.
  • Kawakami F; Department of Pathology, Virginia Mason Hospital & Seattle Medical Center, Seattle, WA, USA.
  • Nakaguro M; Department of Anatomic Pathology, Tokyo Medical University, Tokyo, Japan.
  • Zahir I; Department of Diagnostic Pathology, Kumamoto University Hospital, Kumamoto, Japan.
  • Wakeman K; Departments of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan.
  • Ihrler S; Department of Pathology Mount Sinai Brooklyn, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
  • Chenevert J; Department of Pathology and Laboratory Medicine, University of Louisville, Louisville, KY, USA.
  • Lin YL; DERMPATH Muenchen, Munich, Germany.
  • Westra WH; Pathology Department, L'Hôtel-Dieu de Québec, Centre Hospitalier Universitaire de Québec, Laval University, Quebec, Canada.
  • Gagan J; Division of Diagnostic and Surgical Sciences, School of Dentistry, University of California, Los Angeles, CA, USA.
  • Rooper LM; Department of Pathology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Head Neck Pathol ; 15(4): 1192-1201, 2021 Dec.
Article em En | MEDLINE | ID: mdl-33982215
ABSTRACT
Microsecretory adenocarcinoma (MSA) is a recently described salivary gland tumor with a characteristic histologic and immunophenotypic profile and recurrent MEF2C-SS18 fusions. Because only six cases of MSA have been published, its complete clinicopathologic spectrum is unclear, and its biologic behavior has not been documented. Here, we present an updated and expanded experience of 24 MSA cases. All cases of MSA were obtained from the authors' files. Immunohistochemistry for S100, SOX10, p63, p40, SMA, calponin, and mammaglobin was performed. Molecular analysis was performed by targeted RNA sequencing, SS18 break apart fluorescence in situ hybridization, and/or reverse transcriptase polymerase chain reaction for MEF2C-SS18 fusion. Clinical follow-up was obtained from medical records. A total of 24 MSA cases were collected, from 13 women and 11 men, ranging from 17 to 83 years (mean 49.5 years). The vast majority (23 of 24) arose in the oral cavity, with the palate (n = 14) and buccal mucosa (n = 6) as the most frequent subsites. Tumors showed consistent histologic features including (1) microcystic tubules, (2) flattened intercalated duct-like cells, (3) monotonous oval hyperchromatic nuclei, (4) abundant basophilic luminal secretions, (5) fibromyxoid stroma, and (6) circumscribed borders with subtle infiltration. The tumors were very consistently positive for S100 (24 of 24), p63 (24 of 24), and SOX10 (14 of 14) and negative for p40 (0 of 21), calponin (0 of 12) and mammaglobin (0 of 16), while SMA (4 of 20) was variable. MEF2C-SS18 fusion was demonstrated in 21 of 24 cases; in the remaining 3 cases with insufficient RNA, SS18 break apart FISH was positive. Treatment information was available in 17 cases, all of which were managed with surgery only. In 14 cases with follow-up (1-216 months, mean 30), no cases recurred or metastasized. MSA is a distinct salivary gland neoplasm with remarkably consistent clinical, histologic, immunophenotypic, and genetic features that generally behaves in an indolent manner following surgery alone. These observations solidify MSA as a unique, low-grade salivary gland carcinoma that warrants inclusion in the next version of the WHO classification of head and neck tumors.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias das Glândulas Salivares / Adenocarcinoma Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Head Neck Pathol Assunto da revista: NEOPLASIAS / PATOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias das Glândulas Salivares / Adenocarcinoma Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Head Neck Pathol Assunto da revista: NEOPLASIAS / PATOLOGIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos